End-of-day quote
Shanghai S.E.
23:00:00 07/05/2024 BST
|
5-day change
|
1st Jan Change
|
11.29
CNY
|
-0.70%
|
|
+1.53%
|
+1.07%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
13,431
|
13,944
|
15,311
|
12,619
|
25,774
|
16,709
|
Enterprise Value (EV)
1 |
11,068
|
15,095
|
16,227
|
14,498
|
26,864
|
18,462
|
P/E ratio
|
8.7
x
|
14.2
x
|
11.7
x
|
19.5
x
|
35
x
|
15.9
x
|
Yield
|
3.45%
|
2.11%
|
2.57%
|
1.54%
|
0.86%
|
1.88%
|
Capitalization / Revenue
|
0.43
x
|
0.4
x
|
0.39
x
|
0.35
x
|
0.69
x
|
0.43
x
|
EV / Revenue
|
0.36
x
|
0.43
x
|
0.41
x
|
0.4
x
|
0.71
x
|
0.48
x
|
EV / EBITDA
|
5.3
x
|
7.28
x
|
5.68
x
|
9.21
x
|
16
x
|
11.6
x
|
EV / FCF
|
24.6
x
|
-23
x
|
13.9
x
|
51.8
x
|
34.4
x
|
-16.3
x
|
FCF Yield
|
4.06%
|
-4.34%
|
7.22%
|
1.93%
|
2.91%
|
-6.13%
|
Price to Book
|
1.59
x
|
1.55
x
|
1.53
x
|
1.23
x
|
2.38
x
|
1.45
x
|
Nbr of stocks (in thousands)
|
1,495,880
|
1,495,880
|
1,495,880
|
1,495,880
|
1,495,880
|
1,495,880
|
Reference price
2 |
8.979
|
9.321
|
10.24
|
8.436
|
17.23
|
11.17
|
Announcement Date
|
27/03/19
|
21/04/20
|
28/04/21
|
29/04/22
|
28/04/23
|
26/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
31,006
|
35,285
|
39,312
|
36,234
|
37,593
|
38,824
|
EBITDA
1 |
2,087
|
2,073
|
2,857
|
1,574
|
1,683
|
1,586
|
EBIT
1 |
1,881
|
1,855
|
2,642
|
1,375
|
1,418
|
1,292
|
Operating Margin
|
6.07%
|
5.26%
|
6.72%
|
3.8%
|
3.77%
|
3.33%
|
Earnings before Tax (EBT)
1 |
2,333
|
1,693
|
1,925
|
940.1
|
1,196
|
1,641
|
Net income
1 |
1,545
|
981.3
|
1,311
|
647.1
|
735.7
|
1,048
|
Net margin
|
4.98%
|
2.78%
|
3.33%
|
1.79%
|
1.96%
|
2.7%
|
EPS
2 |
1.032
|
0.6560
|
0.8761
|
0.4326
|
0.4918
|
0.7006
|
Free Cash Flow
1 |
449.1
|
-654.9
|
1,171
|
280.1
|
781.9
|
-1,132
|
FCF margin
|
1.45%
|
-1.86%
|
2.98%
|
0.77%
|
2.08%
|
-2.91%
|
FCF Conversion (EBITDA)
|
21.51%
|
-
|
40.99%
|
17.79%
|
46.47%
|
-
|
FCF Conversion (Net income)
|
29.07%
|
-
|
89.36%
|
43.29%
|
106.28%
|
-
|
Dividend per Share
2 |
0.3098
|
0.1968
|
0.2629
|
0.1298
|
0.1476
|
0.2102
|
Announcement Date
|
27/03/19
|
21/04/20
|
28/04/21
|
29/04/22
|
28/04/23
|
26/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
1,151
|
916
|
1,880
|
1,090
|
1,753
|
Net Cash position
1 |
2,362
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.5555
x
|
0.3206
x
|
1.194
x
|
0.6476
x
|
1.105
x
|
Free Cash Flow
1 |
449
|
-655
|
1,171
|
280
|
782
|
-1,132
|
ROE (net income / shareholders' equity)
|
18.9%
|
11.9%
|
11.9%
|
5.78%
|
6.91%
|
9.18%
|
ROA (Net income/ Total Assets)
|
5.02%
|
4.2%
|
5.24%
|
2.67%
|
2.65%
|
2.2%
|
Assets
1 |
30,772
|
23,358
|
25,008
|
24,200
|
27,815
|
47,573
|
Book Value Per Share
2 |
5.650
|
6.010
|
6.690
|
6.860
|
7.230
|
7.730
|
Cash Flow per Share
2 |
2.490
|
1.780
|
2.380
|
1.870
|
2.850
|
2.590
|
Capex
1 |
262
|
280
|
318
|
286
|
229
|
363
|
Capex / Sales
|
0.84%
|
0.79%
|
0.81%
|
0.79%
|
0.61%
|
0.93%
|
Announcement Date
|
27/03/19
|
21/04/20
|
28/04/21
|
29/04/22
|
28/04/23
|
26/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +1.07% | 2.34B | | +17.42% | 70.67B | | -3.33% | 23.73B | | +7.71% | 8.26B | | -19.61% | 8.07B | | +1.22% | 8.28B | | +5.56% | 4.8B | | +15.41% | 4.26B | | -0.87% | 4.08B | | +23.20% | 3.68B |
Pharmaceuticals Wholesale
|